BLX 0871
Alternative Names: BLX-0871; MLX-0800Latest Information Update: 18 Jan 2024
At a glance
- Originator Biolexis Therapeutics
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus